Baxter International Inc (BAX) : Harfst Associates scooped up 6,637 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 9,301 shares of Baxter International Inc which is valued at $419,196.Baxter International Inc makes up approximately 0.26% of Harfst Associates’s portfolio.
Other Hedge Funds, Including , Parsons Capital Management Incri reduced its stake in BAX by selling 1,495 shares or 3.17% in the most recent quarter. The Hedge Fund company now holds 45,708 shares of BAX which is valued at $2,021,208. Baxter International Inc makes up approx 0.28% of Parsons Capital Management Incri’s portfolio.Cohen Lawrence B reduced its stake in BAX by selling 150 shares or 1.81% in the most recent quarter. The Hedge Fund company now holds 8,125 shares of BAX which is valued at $351,975. Baxter International Inc makes up approx 0.23% of Cohen Lawrence B’s portfolio.Private Trust Co Na boosted its stake in BAX in the latest quarter, The investment management firm added 170 additional shares and now holds a total of 28,892 shares of Baxter International Inc which is valued at $1,251,601. Baxter International Inc makes up approx 0.33% of Private Trust Co Na’s portfolio.Blb&b Advisors reduced its stake in BAX by selling 1,275 shares or 7.09% in the most recent quarter. The Hedge Fund company now holds 16,718 shares of BAX which is valued at $724,224. Baxter International Inc makes up approx 0.14% of Blb&b Advisors’s portfolio.
Baxter International Inc opened for trading at $45.05 and hit $45.67 on the upside on Tuesday, eventually ending the session at $45.5, with a gain of 0.78% or 0.35 points. The heightened volatility saw the trading volume jump to 2,13,45,807 shares. Company has a market cap of $25,128 M.
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.